{"id":2463,"date":"2026-08-30T09:15:33","date_gmt":"2026-08-30T09:15:33","guid":{"rendered":"https:\/\/one-peptides.com\/?p=2463"},"modified":"2026-09-30T11:55:37","modified_gmt":"2026-09-30T11:55:37","slug":"mk-677-vs-ipamorelin-what-the-research-says","status":"publish","type":"post","link":"https:\/\/one-peptides.com\/de\/mk-677-vs-ipamorelin-what-the-research-says\/","title":{"rendered":"MK-677 vs Ipamorelin \u2014 What Does the Research Say?"},"content":{"rendered":"

In brief.<\/strong> MK-677 and ipamorelin activate the same receptor<\/strong> \u2014 GHS-R1a, the ghrelin receptor \u2014 but differ in two central respects. MK-677 (ibutamoren)<\/strong> is a non-peptide, orally active compound<\/strong> with a daily exposure profile and the longest human study in this class: a 12-month randomized trial that reported an increase in lean body mass (Nass et al., 2008). Ipamorelin<\/strong> is a parenterally administered pentapeptide<\/strong> described as the first selective growth hormone secretagogue because it released growth hormone without a significant accompanying rise in cortisol or prolactin (Raun et al., 1998). The comparison therefore concerns signal selectivity and the breadth of human evidence. Both compounds are included in category S2 of the WADA Prohibited List and remain unapproved Research Use Only reagents.<\/em><\/p>\n

This educational article reviews published research on growth hormone secretagogues. Reported effects are limited to the clinical, animal and receptor models described in the cited literature and are not claims about outcomes in readers. This text is not medical advice. One Peptides catalogue compounds are intended solely for laboratory research (Research Use Only).<\/p>\n

How does MK-677 differ from ipamorelin?<\/h2>\n

Both molecules target GHS-R1a and both stimulate the release of endogenous growth hormone; neither is growth hormone or a growth hormone analogue. That is where the similarity ends.<\/p>\n

The first difference is structure and route of administration<\/strong>. MK-677 is a non-peptide compound designed to survive passage through the gastrointestinal tract and was administered orally in research. Ipamorelin is a pentapeptide and was administered parenterally because, like other peptides, it would not survive digestion intact.<\/p>\n

The second difference is signal selectivity<\/strong>. Ipamorelin was deliberately designed so that stimulation of the somatotropic axis would not spill over substantially into neighbouring hormonal axes. The paper that characterized the compound described it as the first selective growth hormone secretagogue: it released growth hormone without a significant rise in cortisol or prolactin and without the pronounced appetite stimulation typical of GHRP-6 (Raun et al., 1998). This selectivity defines its identity in the literature.<\/p>\n

The third difference concerns the evidence base and is often overlooked: the extent of human research is not comparable<\/strong>. MK-677 has a 12-month randomized trial. Ipamorelin is supported mainly by preclinical data.<\/p>\n

Table: MK-677 vs ipamorelin<\/h3>\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Feature<\/th>\nMK-677 (ibutamoren)<\/th>\nIpamorelin<\/th>\n<\/tr>\n
Chemical class<\/th>\nNon-peptide compound (ghrelin mimetic)<\/td>\nPentapeptide<\/td>\n<\/tr>\n
Target receptor<\/th>\nGHS-R1a<\/td>\nGHS-R1a \u2014 the same receptor<\/td>\n<\/tr>\n
Route used in studies<\/th>\nOral<\/td>\nParenteral<\/td>\n<\/tr>\n
Exposure profile<\/th>\nLong, daily profile<\/td>\nShort, pulsatile profile<\/td>\n<\/tr>\n
Signal selectivity<\/th>\nActivates the somatotropic axis; effects on glucose metabolism have been reported<\/td>\nHigh \u2014 without a significant increase in cortisol or prolactin<\/td>\n<\/tr>\n
Effect on appetite<\/th>\nReported<\/td>\nMinor compared with GHRP-6<\/td>\n<\/tr>\n
Longest human study<\/th>\n12 months (randomized)<\/td>\nNo study with a comparable time horizon<\/td>\n<\/tr>\n
Main evidence base<\/th>\nClinical studies in older adults<\/td>\nPreclinical and pharmacological studies<\/td>\n<\/tr>\n
WADA status<\/th>\nProhibited \u2014 category S2<\/td>\nProhibited \u2014 category S2<\/td>\n<\/tr>\n
Approved as a medicine<\/th>\nNo<\/td>\nNo<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

How does MK-677 work, and what have studies shown?<\/h2>\n

MK-677 is a non-peptide GHS-R1a agonist<\/strong> described as a ghrelin mimetic. Structural work on the receptor in complex with ghrelin and ibutamoren showed that both ligands occupy the same binding pocket despite their entirely different chemical structures (Liu et al., 2021), directly confirming their shared molecular target.<\/p>\n

Early studies described stimulation of the growth hormone\u2013insulin-like growth factor I axis after daily oral administration in healthy older adults (Chapman et al., 1996). The strongest reference point remains a 12-month randomized trial published in Annals of Internal Medicine<\/em>. In adults aged 60\u201381 years, one year of oral MK-677 enhanced pulsatile growth hormone secretion and significantly increased lean body mass versus placebo, with generally good tolerability in the study population (Nass et al., 2008). The authors also stated an important limitation: the sample was too small to evaluate functional-performance endpoints.<\/p>\n

Research on this class also notes that stimulation of the growth hormone axis can affect parameters of glucose metabolism, a variable that requires monitoring in each experimental model (Nass et al., 2011). A separate article provides a broader review of MK-677 research<\/a>, while research reagents are grouped in the MK-677 category<\/a>.<\/p>\n

How does ipamorelin work, and what does its selectivity mean?<\/h2>\n

Ipamorelin is a pentapeptide and a GHS-R1a agonist. Its structure includes two D-amino-acid residues and the non-proteinogenic amino acid Aib, design features that increase the molecule’s resistance to enzymatic degradation.<\/p>\n

Its defining feature is selectivity<\/strong>. Older peptides in this family, particularly GHRP-6, released growth hormone effectively but also increased cortisol and prolactin and strongly stimulated appetite, a result consistent with GHS-R1a being the physiological receptor for the hunger hormone ghrelin (M\u00fcller et al., 2015; Camanni et al., 1998). Ipamorelin was designed to reduce this signal spillover substantially, which is why it was described as the first selective growth hormone secretagogue (Raun et al., 1998).<\/p>\n

Evidence for ipamorelin itself comes predominantly from animal models<\/strong>. In adult female rats, both ipamorelin and GHRP-6 increased bone mineral content (Svensson et al., 2000). There is no human study with a time horizon comparable to the year-long MK-677 trial, and this is the most important asymmetry between the compounds.<\/p>\n

A dedicated article examines ipamorelin as a selective secretagogue<\/a>. The reagent is available as ipamorelin 2 mg<\/a> in the ipamorelin category<\/a>.<\/p>\n

Which compound suits which research model?<\/h2>\n

The better question is not which compound is superior, but which experimental tool fits the variable that a model is intended to capture.<\/p>\n

If the study concerns an isolated growth hormone response<\/strong> and a rise in cortisol or prolactin would be a confounding variable, ipamorelin provides the cleaner profile. Selectivity is its defining advantage and is particularly relevant in this experimental context.<\/p>\n

If the study concerns the long-term effects of stimulating the somatotropic axis<\/strong>, MK-677 is the only compound in this class with a one-year randomized human trial and body composition as an endpoint. No comparable dataset exists for ipamorelin.<\/p>\n

If the route of administration<\/strong> matters, MK-677 is orally active whereas ipamorelin requires parenteral administration. This distinction shapes experimental design independently of the compounds’ receptor pharmacology.<\/p>\n

A third branch of this family includes the GHRP-2 and GHRP-6 peptides, which have an intermediate selectivity profile. They are discussed in the MK-677 versus GHRP-2 and GHRP-6 comparison<\/a> and the guide to GHRP secretagogues<\/a>.<\/p>\n

What is known about the safety of both compounds?<\/h2>\n

The comparison is clearly asymmetrical, not because one compound has been shown to be safer, but because one is simply better studied.<\/p>\n

For MK-677, the one-year randomized trial reported generally good tolerability in the study population while stating its limitations explicitly: a small sample and no assessment of functional-performance endpoints (Nass et al., 2008). Separately, stimulation of the growth hormone axis was associated with changes in glucose-metabolism parameters (Nass et al., 2011).<\/p>\n

For ipamorelin, the evidence comes from animal models and pharmacological studies. Its high hormonal selectivity is not equivalent to an established human safety profile; these are separate concepts that are often conflated. The absence of substantial cortisol and prolactin co-release in a model says nothing about long-term human exposure because such studies have not been conducted.<\/p>\n

The uncertainties shared by both compounds include the absence of registration trials, the absence of multi-year exposure data and the absence of an established profile outside the conditions of the published experiments.<\/p>\n

What is the anti-doping status of MK-677 and ipamorelin?<\/h2>\n

Both compounds appear in category S2<\/strong> of the World Anti-Doping Agency Prohibited List: peptide hormones, growth factors, related substances and mimetics. This category explicitly covers growth hormone secretagogues and ghrelin receptor agonists. Substances in S2 are prohibited at all times<\/strong>, both in and out of competition.<\/p>\n

MK-677’s non-peptide structure does not alter its status because category S2 includes mimetics regardless of chemical structure. Anti-doping laboratories have validated analytical methods for detecting compounds in this class (Okano et al., 2010).<\/p>\n

Frequently Asked Questions<\/h2>\n

How does MK-677 differ from ipamorelin?<\/strong> They differ in structure, administration route, signal selectivity and breadth of evidence. MK-677 is a non-peptide, orally active compound with a daily profile and a 12-month randomized human trial. Ipamorelin is a short-acting pentapeptide administered parenterally in research and has a more selective hormonal signal.<\/p>\n

Do MK-677 and ipamorelin activate the same receptor?<\/strong> Yes. Both are agonists of GHS-R1a, the ghrelin receptor.<\/p>\n

What does ipamorelin selectivity mean?<\/strong> In the study that characterized it, ipamorelin released growth hormone without a significant accompanying rise in cortisol or prolactin and without the pronounced appetite signal associated with older GHRPs, especially GHRP-6.<\/p>\n

Is ipamorelin safer than MK-677?<\/strong> The literature does not support that conclusion. Greater hormonal selectivity is not the same as an established safety profile. Ipamorelin lacks human studies with a time horizon comparable to the 12-month MK-677 trial, so fewer data mean greater uncertainty, not proven safety.<\/p>\n

Which compound has the broader human evidence base?<\/strong> MK-677 has the broader long-term human dataset, including a 12-month randomized trial in healthy older adults with body-composition assessment (Nass et al., 2008). Ipamorelin evidence is primarily preclinical and pharmacological.<\/p>\n

Is ipamorelin a form of growth hormone?<\/strong> No. Ipamorelin is a secretagogue: it stimulates the pituitary gland to release endogenous growth hormone. It is neither growth hormone nor a growth hormone analogue. The same distinction applies to MK-677.<\/p>\n

Are both compounds prohibited in sport?<\/strong> Yes. Category S2 of the WADA Prohibited List covers growth hormone secretagogues and ghrelin receptor agonists. MK-677 being non-peptide does not change its status.<\/p>\n

Conclusion \u2014 signal selectivity versus breadth of evidence<\/h2>\n

MK-677 and ipamorelin target the same receptor but differ in nearly every practical consequence of doing so. Ipamorelin is a pentapeptide with the most selective hormonal profile in the family, producing no significant increase in cortisol or prolactin, but its evidence is predominantly preclinical. MK-677 is an orally active non-peptide mimetic with the longest human study in the class, covering 12 months and body composition.<\/p>\n

The practical distinction is therefore selectivity on one side and breadth of evidence on the other. They are not two interchangeable versions of the same experimental tool.<\/p>\n

RUO disclaimer.<\/strong> MK-677 (ibutamoren)<\/a> and ipamorelin in the One Peptides catalogue are chemical reagents intended solely for laboratory and scientific research (Research Use Only). They are not medicines, dietary supplements or products intended for consumption or administration to humans or animals outside a controlled experimental setting. All effects described are findings reported in the cited studies and models, not claims of efficacy or indications for use. This information is educational and scientific and is not medical or pharmaceutical advice. Both compounds appear in category S2 of the WADA Prohibited List.<\/em><\/p>\n

References<\/h2>\n
    \n
  1. Raun K, Hansen BS, Johansen NL et al. (1998). Ipamorelin, the first selective growth hormone secretagogue<\/cite><\/a><\/li>\n
  2. Nass R, Pezzoli SS, Oliveri MC et al. (2008). Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial<\/cite><\/a><\/li>\n
  3. Svensson J, Lall S, Dickson SL et al. (2000). The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats<\/cite><\/a><\/li>\n
  4. Liu H, Sun D, Myasnikov A et al. (2021). Structural basis of human ghrelin receptor signaling by ghrelin and the synthetic agonist ibutamoren<\/cite><\/a><\/li>\n
  5. Chapman IM, Bach MA, Van Cauter E et al. (1996). Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects<\/cite><\/a><\/li>\n
  6. M\u00fcller TD, Nogueiras R, Andermann ML et al. (2015). Ghrelin<\/cite><\/a><\/li>\n
  7. Camanni F, Ghigo E, Arvat E (1998). Growth hormone-releasing peptides and their analogs<\/cite><\/a><\/li>\n
  8. Nass R, Gaylinn BD, Thorner MO (2011). The role of ghrelin in GH secretion and GH disorders<\/cite><\/a><\/li>\n
  9. Okano M, Sato M, Kageyama S et al. (2010). Determination of growth hormone secretagogue pralmorelin (GHRP-2) and its metabolite in human urine by liquid chromatography\/electrospray ionization tandem mass spectrometry<\/cite><\/a><\/li>\n<\/ol>\n

    Regulatory source: World Anti-Doping Agency, Prohibited List, category S2 (peptide hormones, growth factors, related substances and mimetics): WADA Prohibited List<\/a>.<\/em><\/p>\n